Imatinib and ruxolitinib association: first experience in two patients

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

“…literature. [2][3][4][5][6][7][8] Also, the results of research studies concerning mutational profiles of patients with MPN confirmed the coexistence of JAK2 V617F mutation and BCR-ABL1 fusion gene in about 0.2%-0.5% of patients. 9,10 Interestingly, the laboratory and clinical data in such cases indicated that in about 88.3% of cases BCR-ABL1 and JAK2 V617F-mutated cells represented 2 different clones.…”

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

“…However, it has to be admitted that the coexistence of CML and BCR‐ABL1 ‐negative myeloproliferative neoplasms is not an infrequent finding (Iurlo et al , ), indicating the importance of searching for JAK2 V617F, CALR and MPL (the latter only if JAK2 is unmutated) mutations in patients who present with leucocytosis and extreme thrombocytosis. A bone marrow biopsy should always be performed in this particular situation; indeed, an expert haemopathologist is usually able to provide additional information on megakaryocyte morphology and distribution in the bone marrow microenvironment, so indicating the coexistence of two different haematological disorders.…”

Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre

“…Interestingly, we were able to measure SS before and after ruxolitinib treatment in three patients, and the results showed that the improvements in constitutional symptoms and spleen size were paralleled by a reduction in SS (Table ). This finding suggests that the technique can also be used with the primary aim of facilitating the assessment of the responses of PMF patients to innovative treatments with JAK1/2 inhibitors (such as ruxolitinib), which may improve bone marrow fibrosis (Kvasnicka et al , ; Wilkins et al , ; Iurlo et al , ), although this needs to be confirmed by further studies involving larger numbers of patients.…”